Product Description
The resulting product BGC101 has the potential for treatment of various vascular conditions such as coronary heart disease, stroke and peripheral ischemia.
Mechanisms of Action: Autologous Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intramuscular
FDA Designation: Fast Track - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioGenCell
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Israel, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Arterial Disease|Peripheral Vascular Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EnEPC-CLI-01 | P2 |
Active, not recruiting |
Peripheral Arterial Disease |
2027-12-31 |
2025-05-02 |
Treatments |
|
| EnEPC-CLI | P2 |
Active, not recruiting |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2017-07-01 |
12% |
2025-06-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/19/2024 |
News Article |
BioGenCell Receives FDA Fast Track Designation with Expanded Access for BGC101 |